How Fungal-Fighting Peptides Reduce Cell Communication via Vesicles

Jim Crocker
23rd September, 2025

How Fungal-Fighting Peptides Reduce Cell Communication via Vesicles

Fluorescence microscopy demonstrates that the EntV68 protein and a derived 12-amino acid peptide bind to the cell surfaces of C. albicans (a–d), C. parapsilosis (e), and C. auris (f) in distinct focal patterns (g–k) and penetrate throughout fungal biofilms (l–m).

Image adapted from: Cesare et al. / CC BY (Source)

Key Findings

  • Researchers at multiple universities studied Candida albicans infections, a growing healthcare concern, focusing on reducing fungal virulence rather than killing the fungus
  • A peptide called EntV weakens Candida’s ability to cause infection by disrupting the release of extracellular vesicles (EVs), which are crucial for biofilm formation
  • EntV binds to the fungal cell surface and interferes with the ESCRT pathway, a cellular system involved in EV production, ultimately reducing the amount of EVs secreted by Candida albicans
Candida albicans is a common fungus that can cause infections ranging from thrush to life-threatening systemic diseases, particularly in individuals with weakened immune systems. The increasing prevalence of candidiasis, coupled with the limited number of effective antifungal drugs and the rise of drug-resistant strains, presents a significant medical challenge[2]. Researchers at the University of Texas McGovern Medical School, alongside colleagues from the University of Wisconsin, Massachusetts General Hospital, Harvard Medical School, and the University of California Irvine, have been investigating a novel approach to combat these infections, focusing not on killing the fungus directly, but on reducing its ability to cause disease – its virulence. The study[1] centers around a peptide called EntV, previously shown to be effective in animal models of Candida infection. Unlike traditional antifungals, EntV doesn’t kill the fungus or stop its growth; instead, it weakens its capacity to infect. This is a crucial distinction, as it bypasses the common problem of fungi developing resistance to drugs that directly target their survival. The central question driving this research was to understand how EntV achieves this reduction in virulence. The research team employed a variety of techniques – examining cells, analyzing their biochemical processes, studying their genetic makeup, and observing their behavior – to pinpoint the mechanism of action. They found that EntV peptides attach to the outer layer of the fungal cell, specifically associating with structures called extracellular vesicles (EVs). EVs are tiny packages released by cells that play a vital role in communication and, critically, in biofilm formation. Biofilms are communities of fungi encased in a protective matrix, making them significantly harder to eradicate with antifungals. Further investigation revealed a connection between EntV’s activity and a cellular pathway known as the ESCRT pathway. This pathway is responsible for intracellular vesicular trafficking – essentially the system cells use to move materials around inside them. Mutations in the ESCRT pathway altered the fungus’s sensitivity to EntV, suggesting a direct link between the two. Importantly, treatment with EntV significantly reduced the amount of EVs secreted by Candida albicans. These findings propose a new mechanism of antifungal action. EntV appears to disrupt the release of EVs, thereby hindering biofilm formation and reducing the fungus’s ability to cause infection. This is particularly relevant given the increasing recognition of the role EVs play in fungal pathogenesis[2]. The study builds on earlier work demonstrating the challenges posed by invasive fungal infections and the selective pressure driving antifungal resistance[3]. While traditional antifungals face limitations due to fungal adaptation, targeting virulence factors like EV secretion offers a potential route to circumvent these issues. The researchers also note that lipopeptide antibiotics, a broader class of compounds that includes EntV, have shown promise as both pharmaceutical drugs and biocontrol agents, with several derivatives already in clinical trials[4]. The discovery of EntV’s mechanism of action further strengthens its potential as a therapeutic agent, especially against drug-resistant strains. The work contributes to a growing understanding of fungal virulence and provides a foundation for the development of new strategies to combat candidiasis and other fungal infections.

BiochemPlant ScienceMycology

References

Main Study

1) The antifungal mechanism of EntV-derived peptides is associated with a reduction in extracellular vesicle release

Published 22nd September, 2025

https://doi.org/10.1371/journal.ppat.1013519

Related Studies

2) Candida sp. Infections in Patients with Diabetes Mellitus.

https://doi.org/10.3390/jcm8010076

3) Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

https://doi.org/10.3390/antibiotics9120877

4) Fungi-derived lipopeptide antibiotics developed since 2000.

https://doi.org/10.1016/j.peptides.2019.02.002


Related Articles

An unhandled error has occurred. Reload 🗙